Obesity, Overweight
Conditions
Brief summary
This study is testing how overweight and obesity affect cardiovascular disease (CVD) prevalence, risk factors, and mortality among Chinese adults using nationally representative CCDRFS (China Chronic Disease and Risk Factor Surveillance) data. The purpose of the study is to characterize trends and determinants of CVD in adults with overweight or obesity and to quantify the excess mortality and population burden attributable to overweight/obesity. Participants will not receive any study medicine as this is an observational analysis of existing survey and mortality data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys. The study will last for the duration needed to analyse the CCDRFS datasets and linked mortality follow-up.
Interventions
OTHERNo treatment given
No treatment given
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Permanent residents (residing in the survey counties/cities/districts for ≥6 months) from the 2013, 2018, and 2023 CCDRFS surveys; With complete information from physical examinations, blood biochemical tests, and questionnaires, including: * Demographic information (age, sex, urban/rural classification, etc.); * Height, weight, waist circumference, blood pressure; * Blood biochemical indicators (fasting/2-hour postprandial blood glucose, glycated hemoglobin, lipid panel: high density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, total cholesterol, serum creatinine, etc.); * Routine urine indicators: urine protein (or urine microalbumin); self-reported prevalence of CVD and major chronic diseases (e.g., hypertension, diabetes, dyslipidemia, etc.); * Major behavioral risk factors (smoking, alcohol consumption, physical activity, dietary patterns, etc.); * Information on concomitant medication use.
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary End point | 2013-2023 | Primary outcome: prevalence of cardiovascular disease (CVD), defined as the proportion of participants reporting a physician diagnosis or self-reported history of coronary heart disease, stroke, heart failure, or peripheral artery disease. We will summarize how common CVD and related conditions are in the study population. Categorical variables (e.g., overweight/obesity, central obesity, prior diagnoses) will be reported as counts and percentages. Continuous variables (e.g., BMI, waist circumference) will be reported as n, mean, and SD. For each survey year (2013, 2018, 2023) we will compute crude and age-standardized, population-weighted prevalence estimates. Trends over time will be assessed using Joinpoint regression to estimate the Average Annual Percent Change (AAPC) with 95% confidence intervals. |
Countries
China
Contacts
STUDY_DIRECTORClinical Transparency dept. 2834
Novo Nordisk A/S
Outcome results
None listed